Article Text

Download PDFPDF
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge
  1. Daniel Steven Sanders1,
  2. Thomas Fennell2 and
  3. Mohammad Muhsin Chisti3
  1. 1 Department of Internal Medicine, McLaren-Oakland Hospital, Pontiac, Michigan, USA
  2. 2 Department of Pathology, Oakland University William Beaumont Hospital, Royal Oak, Michigan, USA
  3. 3 Department of Hematology and Medical Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA
  1. Correspondence to Dr Daniel Steven Sanders, daniel.sanders1{at}


A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow biopsy to assess haematological response after 6 months of initial lenalidomide therapy. Subsequent bone marrow biopsies revealed persistent MDS with del(5q) in addition to a small atypical mast cell population with >25% of mast cells with spindle-shaped morphology and immunohistochemistry characteristics consistent with mastocytosis. Molecular testing on the bone marrow was positive for cKIT D816V and the patient was diagnosed with systemic mastocytosis (SM) with an associated haematological neoplasm. MDS with SM is well known to be associated; however, to the best of our knowledge, only one prior case report identifies MDS with del(5q) and associated cKIT D816V positive mastocytosis. While the exact clonal origin of both chromosomal aberrations is unclear, this case illustrates the therapeutic efficacy of lenalidomide in a patient with MDS with del(5q) and rarely associated cKIT positive SM.

  • malignant and benign haematology
  • haematology (incl blood transfusion)
  • oncology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors DSS, TF and MMC were all involved equally in writing the manuscript. Each author has reviewed the final version of the manuscript and approves it for publication.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.